FindTrial
Sign In

Study to Assess the Efficacy of(IHRA)software in Early Detection of Chronic Diseases (Type 2 Diabetes, Hypertension and Dyslipidemia)

A cross sectional pilot study to Assess the Efficacy of Intelligent Health Risk Assessment (IHRA) software in Early Detection of Chronic Diseases (Type 2 Diabetes, Hypertension and Dyslipidemia)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/035507
Enrollment
500
Registered
2021-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Aarca Research India Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female participants aged � 25 years and � 65 years at the time of consent 2. Participants at high risk of developing one of the following diseases: - Type 2 diabetes - Hypertension - Dyslipidemia 3. Participants who can and are willing to provide Informed Consent. 4. Participants who understand and are willing to participate in the clinical study and can comply with clinical trial protocol requirements.

Exclusion criteria

Exclusion criteria: 1. Patients with established coronary artery disease as detected by angiogram/TMT/ECG or patients with symptoms suggestive or ischemic heart disease. 2. Patients with established Type 2 diabetes, hypertension and dyslipidemia. 3. Female patients with gestational diabetes. 4. Female patients who are pregnant at the time of screening 5. Patients with diagnosed thyroid dysfunction 6. Patients with Type 1 diabetes. 7. Patients with any other co-morbidities /medical illness

Design outcomes

Primary

MeasureTime frame
1. For type 2 Diabetes, OGTT blood test will be considered as the Gold Standard. 2. Sensitivity and Specificity of IHRA in comparison with OGTT 3. For Dyslipidemia, fasting LDL and Total Cholesterol blood tests will be considered as the Gold Standard. 4. Sensitivity and Specificity of IHRA in comparison with fasting blood LDL levels and 5. Sensitivity and Specificity of IHRA in comparison with fasting blood Total cholesterol levelsTimepoint: Few hours (2-3 hours)—

Secondary

MeasureTime frame
1. Correlation between IHRA score and OGTT, FPG, LDL, TC blood tests and MABP readingsTimepoint: few hours (2-3 hours)—

Countries

India

Contacts

Public ContactMr Vairamuthu Ammaiyappan

iDD Research Solutions INC

yogesh@iddresearch.com9717832255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026